The structural neural substrates of persistent negative symptoms in first-episode of non-affective psychosis: A voxel-based morphometry study

Frontiers in Psychiatry

Volumn 3, Issue MAY, 2012, Pages

  Benoit, Audrey ^a   Bodnar, Michael ^a,b   Malla, Ashok K ^a,b   Joober, Ridha ^a,b   Lepage, Martin ^a,b  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

First episode psychosis; Frontal lobe; Magnetic resonance imaging; Neural substrates; Persistent negative symptoms; Voxel based morphometry

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FUSIFORM GYRUS; GRAY MATTER; HUMAN; HUMAN TISSUE; INFERIOR FRONTAL GYRUS; LEFT HEMISPHERE; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; NEUROANATOMY; NEUROIMAGING; ORBITAL CORTEX; PARAHIPPOCAMPAL GYRUS; RIGHT HEMISPHERE; SUPERIOR TEMPORAL GYRUS; VOXEL BASED MORPHOMETRY;

EID: 84866844529     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2012.00042     Document Type: Article

References (68)

1. Addington, D., Addington, J., and Maticka-Tyndale, E. (1993). Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry Suppl. 22, 39-44.
2. Anderson, J. E., Wible, C. G., McCar-ley, R. W., Jakab, M., Kasai, K., and Shenton, M. E. (2002). An MRI study of temporal lobe abnormalities and negative symptoms in chronic schizophrenia. Schizophr. Res. 58, 123-134.
3. Andreasen, N. C. (1984a). Modified Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa.
4. Andreasen, N. C. (1984b). Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa.
5. Andreasen, N. C., Carpenter, W. T. Jr., Kane, J. M., Lasser, R. A., Marder, S. R., and Weinberger, D. R. (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162, 441-449.
6. Andreasen, N. C., Olsen, S. A., Dennert, J. W., and Smith, M. R. (1982). Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms. Am. J. Psychiatry 139, 297-302.
7. Ashburner, J., and Friston, K. J. (2000). Voxel-based morphometry-the methods. Neuroimage 11, 805-821.
8. Ashburner, J., and Friston, K. J. (2001). Why voxel-based morphometry should be used. Neuroimage 14, 1238-1243.
9. Baare, W. F., Hulshoff Pol, H. E., Hij-man, R., Mali, W P., Viergever, M. A., and Kahn, R. S. (1999). Volumetric analysis of frontal lobe regions in schizophrenia: relation to cognitive function and symptomatology. Biol. Psychiatry 45, 1597-1605.
10. Badcock, J. C., Fukuda, M., Gottesmann, C., Iwanami, A., Kasai, K., Lerner, V., Maybery, M. T., Miodownik, C., Moore, K., Nakagome, K., Pinika-hana, J., Rogers, M. A., Sollberger, D., Walkup, J., Waters, F. A. V., and Yamasue, H. (2007). Psychology and Schizophrenia. New York: Nova Science Publishers, Inc.
11. Berge, D., Carmona, S., Rovira, M., Bulbena, A., Salgado, P., and Vilar-roya, O. (2011). Gray matter volume deficits and correlation with insight and negative symptoms in first-psycho tic-episode subjects. Acta Psy-chiatr. Scand. 123, 431-439.
12. Bodnar, M., Harvey, P. O., Malla, A. K., Joober, R., and Lepage, M. (2011). The parahippocampal gyrus as a neural marker of early remission in first-episode psychosis: a voxel-based morphometry study. Clin. Schizophr. Relat. Psychoses 4, 217-228.
13. Buchanan, R. W. (2007). Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 33, 1013-1022.
14. Buchanan, R. W., Breier, A., Kirk-patrick, B., Elkashef, A., Munson, R. C., Gellad, F., and Carpenter, W. T. Jr. (1993). Structural abnormalities in deficit and nondeficit schizophrenia. Am. J. Psychiatry 150, 59-65.
15. Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., and Carpenter, W. T. (2007). The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164, 1593-1602.
16. Carpenter, W T. Jr., Heinrichs, D. W., and Wagman, A. M. (1988). Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry 145, 578-583.
17. Cascella, N. G., Fieldstone, S. C., Rao, V A., Pearlson, G. D., Sawa, A., and Schretlen, D. J. (2010). Gray-matter abnormalities in deficit schizophrenia. Schizophr. Res. 120, 63-70.
18. Cassidy, C. M., Rabinovitch, M., Schmitz, N., Joober, R., and Malla, A. (2010). A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis. J. Clin. Psy-chopharmacol. 30, 64-67.
19. Chang, W C, Hui, C. L., Tang, J. Y., Wong, G. H., Lam, M. M., Chan, S. K., and Chen, E. Y. (2011). Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr. Res. 133, 22-28.
20. Chouinard, G., and Margolese, H. C. (2005). Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr. Res. 76, 247-265.
21. First, M. B., Spitzer, R. L., Gibbon, M., and Williams, J. B. W. (1998). Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P & SCID-I/NP), Version 2. New York: New York Psychiatric Institute, Biometrics Research.
22. First, M. B., Spitzer, R. L., Gibbon, M., and Williams, J. B. W. (2007). Structured Clinical Interview for DSM-IV-TR Axis I Disorders - Non-patient Edition (SCID-I/NP, 1/2007 revision). New York, NY: New York State Psychiatric Institute.
23. Galderisi, S., Quarantelli, M., Volpe, U., Mucci,A., Cassano, G. B.,Invernizzi, G., Rossi, A., Vita, A., Pini, S., Cassano, P., Daneluzzo, E., De Peri, L., Stratta, P., Brunetti, A., and Maj, M. (2008). Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophr. Bull. 34, 393-401.
24. Glenthoj, A., Glenthoj, B. Y., Mack-eprang, T., Pagsberg, A. K., Hem-mingsen, R. P., Jernigan, T. L., and Baare, W F. (2007). Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Res. 154, 199-208.
25. Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hay-den, D. L., McCarley, R., and Coyle, J. T. (1999). A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry 56,21-27.
26. Good, C. D., Johnsrude, I. S., Ashburner, J., Henson, R. N., Friston, K. J., and Frackowiak, R. S. (2001). A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 14, 21-36.
27. Gur, R. E., Cowell, P., Turetsky, B. I., Gallacher, F., Cannon, T., Bilker, W., and Gur, R. C. (1998a). A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch. Gen. Psychiatry 55, 145-152.
28. Gur, R. E., Maany, V., Mozley, P. D., Swanson, C., Bilker, W., and Gur, R. C. (1998b). Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am. I Psychiatry 155, 1711-1717.
29. Gur, R. E., Cowell, P. E., Latshaw, A., Turetsky, B. I., Grossman, R. I., Arnold, S. E., Bilker, W. B., and Gur, R. C. (2000). Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. Arch. Gen. Psychiatry 57, 761-768.
30. Gur, R. E., Mozley, P. D., Shtasel, D. L., Cannon, T. D., Gallacher, F., Turetsky, B., Grossman, R., and Gur, R. C. (1994). Clinical subtypes of schizophrenia: differences in brain and CSF volume. Am. J. Psychiatry 151, 343-350.
31. Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., and Lichtenstein, M. (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 56, 29-36.
32. Hollingshead, A. (1965). Two-Factor Index of Social Position. New Haven, CN: Yale University Press.
33. Honey, G., and Bullmore, E. (2004). Human pharmacological MRI. Trends Pharmacol. Sci. 25, 366-374.
34. Hulshoff Pol, H. E., and Kahn, R. S. (2008). What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr. Bull. 34, 354-366.
35. Jensen, B., and Regier, L. D. (ed.). (2010). Drug Comparison Charts, 7th Edn. Saskatoon, SK: RxFiles Academic Detailing Program.
36. Johnson, D. P., Penn, D. L., Fredrickson, B. L., Meyer, P. S., Kring, A. M., and Brantley, M. (2009). Loving-kindness meditation to enhance recovery from negative symptoms of schizophrenia. J. Clin. Psychol. 65, 499-509.
37. Kirkpatrick, B., and Buchanan, R. W. (1990). The neural basis of the deficit syndrome of schizophrenia. J. Nerv. Ment. Dis. 178, 545-555.
38. Kirkpatrick, B., Buchanan, R. W., McKenney, P. D., Alphs, L. D., and Carpenter, W. T. Jr. (1989). The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 30, 119-123.
39. Kirkpatrick, B., Fenton, W. S., Carpenter, W. T. Jr., and Marder, S. R. (2006). The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 32, 214-219.
40. Lacerda, A. L., Hardan, A. Y., Yorbik, O., Vemulapalli, M., Prasad, K. M., and Keshavan, M. S. (2007). Morphology of the orbitofrontal cortex in first-episode schizophrenia: relationship with negative symptomatology. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 510-516.
41. Lieberman, J., Chakos, M., Wu, H., Alvir, J., Hoffman, E., Robinson, D., and Bilder,R. (2001). Longitudinal study of brain morphology in first episode schizophrenia. Biol. Psychiatry 49, 487-499.
42. Majak, K., and Pitkanen, A. (2003). Projections from the periamygdaloid cortex to the amygdaloid complex, the hippocampal formation, and the parahippocampal region: a PHA-L study in the rat. Hippocampus 13, 922-942.
43. Makinen, J., Miettunen, J., Isohanni, M., and Koponen, H. (2008). Negative symptoms in schizophrenia: a review. Nord. J. Psychiatry 62, 334-341.
44. Malla, A., Norman, R., McLean, T., Scholten, D., and Townsend, L. (2003). A Canadian programme for early intervention in non-affective psychotic disorders. Aust. N. Z. J. Psychiatry 37, 407-413.
45. Malla, A. K., Norman, R. M., Takhar, J., Manchanda, R., Townsend, L., Scholten, D., and Haricharan, R. (2004). Can patients at risk for persistent negative symptoms be identified during their first episode of psychosis. J. Nerv. Ment. Dis. 192, 455-463.
46. Malla, A. K., Takhar, J. J., Norman, R. M., Manchanda, R., Cortese, L., Haricharan, R., Verdi, M., and Ahmed, R. (2002). Negative symptoms in first episode non-affective psychosis. Acta Psychiatr. Scand. 105, 431-439.
47. Milev, P., Ho, B. C., Arndt, S., and Andreasen, N. C. (2005). Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 162, 495-506.
48. Moncrieff, J., and Leo, J. (2010). A systematic review of the effects of antipsychotic drugs on brain volume. Psychol. Med. 40, 1409-1422.
49. Nesvag, R., Saetre, P., Lawyer, G., Jon-sson, E. G., and Agartz, I. (2009). The relationship between symptom severity and regional cortical and grey matter volumes in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 482-490.
50. Norman, R. M., Malla, A. K., Cortese, L., and Diaz, F. (1996). A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. Schizophr. Res. 19, 73-85.
51. Oldfield, R. C. (1971). The assessment and analysis of handedness: the Edinburgh inventory. Neuropsy-chologia 9, 97-113.
52. Preuss, U. W., Zetzsche, T., Jager, M., Groll, C., Frodl, T., Bottlender, R., Leinsinger, G., Hegerl, U., Hahn, K., Moller, H. J., and Meisenzahl, E. M. (2005). Thalamic volume in first-episode and chronic schizophrenic subjects: a volumetric MRI study. Schizophr. Res. 73, 91-101.
53. Quarantelli, M., Larobina, M., Volpe, U., Amati, G., Tedeschi, E., Cia-rmiello, A., Brunetti, A., Galderisi, S.,andAlfano,B. (2002).Stereotaxy-based regional brain volumetry applied to segmented MRI: validation and results in deficit and nond-eficit schizophrenia. Neuroimage 17, 373-384.
54. Rajarethinam, R., DeQuardo, J. R., Miedler, J., Arndt, S., Kirbat, R., Brunberg, J. A., and Tandon, R. (2001). Hippocampus and amygdala in schizophrenia: assessment of the relationship of neuroanatomy to psychopathology. Psychiatry Res. 108, 79-87.
55. Rector, N. A., Seeman, M. V., and Segal, Z. V. (2003). Cognitive therapy for schizophrenia: a preliminary randomized controlled trial. Schizophr. Res. 63,1-11.
56. Saijo, T., Abe, T., Someya, Y., Sassa, T., Sudo, Y., Suhara, T., Shuno, T., Asai, K., and Okubo, Y (2001). Ten year progressive ventricular enlargement in schizophrenia: an MRI mor-phometrical study. Psychiatry Clin. Neurosci. 55,41-47.
57. Shenton, M. E., Dickey, C. C., Frumin, M., and McCarley, R. W. (2001). A review of MRI findings in schizophrenia. Schizophr. Res. 49, 1-52.
58. Sigmundsson, T., Suckling, J., Maier, M., Williams, S., Bullmore, E., Greenwood, K., Fukuda, R., Ron, M., and Toone, B. (2001). Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am. J. Psychiatry 158, 234-243.
59. Stein, E. A. (2001). fMRI: a new tool for the in vivo localization of drug actions in the brain. J. Anal. Toxicol. 25,419-424.
60. Szendi, I., Kiss, M., Racsmany, M., Boda, K., Cimmer, C., Voros, E., Kovacs, Z. A., Szekeres, G., Galsi, G., Pleh, C., Csernay, L., and Janka, Z. (2006). Correlations between clinical symptoms, working memory functions and structural brain abnormalities in men with schizophrenia. Psychiatry Res. 147, 47-55.
61. Turetsky, B., Cowell, P. E., Gur, R. C., Grossman, R. I., Shtasel, D. L., and Gur, R. E. (1995). Frontal and temporal lobe brain volumes in schizophrenia. Relationship to symptoms and clinical subtype. Arch. Gen. Psychiatry 52, 1061-1070.
62. Turkington, D., Sensky, T., Scott, J., Barnes, T. R., Nur, U., Siddle, R., Hammond, K., Samarasekara, N., and Kingdon, D. (2008). A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: a five-year follow-up. Schizophr. Res. 98, 1-7.
63. Tzourio-Mazoyer, N., Landeau, B., Pap-athanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., and Joliot, M. (2002). Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15, 273-289.
64. Wechsler, D. (1997). Wechsler Adult Intelligence Scale, 3rd Edn. San Antonio, TX: The Psychological Corporation.
65. Williams, G. V., and Castner, S. A. (2008). Dissecting the biology of prefrontal cortical dysfunction in schizophrenia: deficiency in mnemonic processing. Biol. Psychiatry 64,1024-1025.
66. Woods, S. W. (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics.J. Clin. Psychiatry 64, 663-667.
67. Yoshida, T., McCarley, R. W., Nakamura, M., Lee, K., Koo, M. S., Bouix, S., Salisbury, D. F., Morra, L., Shenton, M. E., and Niznikiewicz, M. A. (2009). A prospective longitudinal volumetric MRI study of superior temporal gyrus gray matter and amygdala-hippocampal complex in chronic schizophrenia. Schizophr. Res. 113, 84-94.
68. Zald, D., and Kim, S. (2001). "The orbitofrontal cortex," in The Frontal Lobes and Neuropsychiatric Illness, 1st Edn, eds S. Salloway, P. Mal-loy, and J. Duffy (Washington, DC: American Psychiatric Publishing, Inc.), 33-69.